In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists ... and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as ...

Of note, however, at peak times, the oral DehydraTECH-tirzepatide-induced insulin levels were as much as approximately 100% higher than those from the Zepbound® injection. "Lexaria is delighted ...

Of note, however, at peak times, the oral DehydraTECH-tirzepatide-induced insulin levels were as much as approximately 100% higher than those from the Zepbound® injection. "Lexaria is ...